Here, we utilized three NSCLC cell lines with different genotypes (regarding EGFR and KRAS mutational status, different copy number gains and losses of genes relevant for lung cancer) to investigate the molecular mechanisms of the combination of the pan-HDACi PS with erlotinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.